Asensus Surgical Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Asensus Surgical Inc (ASXC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Asensus Surgical Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 8M vs 230,478M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-25.1% annualized vs trailing 12 months), vs decelerating (-14.8%) for its tracked peer group.
- Growth: Asensus Surgical Inc generated 53.7% revenue growth year over year in Q2 2024, vs -2.2% for its tracked competitors combined.
- Profitability: Its -1,663.4% net margin compares with 16.2% for the peer group.
- Peer revenue share: Asensus Surgical Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.04M compares with $0.49M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ASXC Sales vs. its Competitors, Q2 2024
Asensus Surgical Inc reported revenue growth of 53.72 % year on year in Q2 2024, above its competitors' combined revenue change of -2.21 %.
With a net margin of -1,663.37 %, Asensus Surgical Inc reported lower profitability than its competitors (16.19 %).
Asensus Surgical Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Asensus Surgical Inc vs. its Competitors, Q2 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Asensus Surgical Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Asensus Surgical Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Asensus Surgical Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 53.7% for Asensus Surgical Inc. Asensus Surgical Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Asensus Surgical Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Asensus Surgical Inc | No | Yes | Yes | Yes |
| Competitors combined (39) | ||||
| High-Confidence Competitors (3) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 75.00 % (6 of 8) | 62.50 % (5 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ASXC Stock Performance relative to its Competitors
ASXC Stock Performance relative to High-Confidence Competitors
ASXC Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Autonomix Medical Inc | 282.9% | Outperformed |
| 2 | Axogen inc | 282.9% | Outperformed |
| 3 | Tenon Medical Inc | 282.9% | Outperformed |
| 4 | Monogram technologies inc | 282.9% | Outperformed |
| 5 | Bioventus Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Asensus Surgical Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Asensus Surgical Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Asensus Surgical Inc | - | 8.27 |
| Johnson and Johnson | 662,243.14 | 97,929.00 |
| Intuitive Surgical Inc | 147,096.84 | 11,296.30 |
| Medtronic Plc | 113,821.31 | 37,542.00 |
| Stryker Corp | 107,775.06 | 25,837.00 |
| Boston Scientific Corporation | 64,515.13 | 20,997.00 |
| SUBTOTAL | 1,210,761.74 | 231,886.36 |
Sign in to see all competitors of Asensus Surgical Inc .
Sources: Asensus Surgical Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Asensus Surgical Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Asensus Surgical Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Intuitive Surgical Inc | Named by the company | 85% |
| Ss Innovations International Inc | Named by the company | 85% |
| Medtronic plc | Named by the company | 85% |
| CareSyntax Inc | Named by the company | 85% |
| CMR Surgical Ltd | Named by the company | 85% |
| Senhance Systems | Named by the company | 85% |
| Distalmotion SA | Named by the company | 85% |
| Vicarious Surgical Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Asensus Surgical Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Asensus Surgical Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.26 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Boston Scientific Corporation | Cardiovascular 67.31 % |
| Edwards Lifesciences Corporation | United States 57.64 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Asensus Surgical Inc .
Asensus Surgical Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Asensus Surgical Inc | - | 41,330 | -418,995 |
| Johnson and Johnson | 662,243 | 695,518 | 149,411 |
| Intuitive Surgical Inc | 147,097 | 663,668 | 185,530 |
| Medtronic Plc | 113,821 | 395,179 | 55,463 |
| Stryker Corp | 107,775 | 461,375 | 66,589 |
| Boston Scientific Corporation | 64,515 | 355,881 | 62,186 |
| PEERS TOTAL | 1,210,762 | 492,238 | 79,325 |
Sign in to see all peers for Asensus Surgical Inc .
Asensus Surgical Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| Intuitive Surgical Inc | Geographic Distribution, Foreign 30.41 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.26 % |
| Boston Scientific Corporation | United States 63.11 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Asensus Surgical Inc .
Asensus Surgical Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | -36.28 % | 53.35 % (avg) | -89.6 pp |
| Operating Margin | -1,080.30 % | industry median | -1,067.7 pp |
| EBITDA Margin | -964.02 % | -6.82 % (avg) | -957.2 pp |
| Capital Intensity (Capex / Revenue) | - | 5.43 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Asensus Surgical Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | 238.94 % | -64.60 % | -62.78 % | 159.28 % | -13.91 % | 7.72 % |
| Operating Margin | - | -870.86 % | -203.93 % | -1,811.92 % | -1,902.02 % | -784.97 % | -1,067.86 % | - |
| Return on Invested Capital | -37.15 % | -20.37 % | -12.51 % | -67.00 % | -46.08 % | -16.82 % | -29.83 % | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Asensus Surgical Inc's Strategic Group Map
Every company in Asensus Surgical Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Asensus Surgical Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Asensus Surgical Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Asensus Surgical Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Asensus Surgical Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 1,067.7 points below the industry median.
- Return on equity 414.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-25.1% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-14.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Asensus Surgical Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Asensus Surgical Inc | 0.79 | 1.44 | 0.19 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Intuitive Surgical Inc | 1.43 | 4.80 | - |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Boston Scientific Corporation | 0.25 | 1.54 | 0.47 |
Sign in to see all peers for Asensus Surgical Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Asensus Surgical Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Asensus Surgical Inc | Q2 2024 | +53.7 % | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Intuitive Surgical Inc | Q2 2026 | +29.3 % | +23.9 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Boston Scientific Corporation | Q2 2026 | +7.5 % | +13.8 % |
| PEERS TOTAL | +8.5 % | +19.4 % |
Sign in to see all peers for Asensus Surgical Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Asensus Surgical Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Asensus Surgical Inc | Q2 2024 | -33.3 % | +8.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Intuitive Surgical Inc | Q2 2026 | +13.4 % | -27.5 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Boston Scientific Corporation | Q2 2026 | -2.6 % | +24.2 % |
Sign in to see all peers for Asensus Surgical Inc .
Asensus Surgical Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Asensus Surgical Inc | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Intuitive Surgical Inc | 15.63% | 17.11% | 17.82% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Boston Scientific Corporation | 8.34% | 9.91% | 14.77% |
Sign in to see all peers for Asensus Surgical Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Asensus Surgical Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Asensus Surgical Inc | - | - |
| Johnson and Johnson | 31.41 | 6.76 |
| Intuitive Surgical Inc | 47.27 | 13.02 |
| Medtronic Plc | 260.50 | 3.03 |
| Stryker Corp | 28.93 | 4.17 |
| Boston Scientific Corporation | 17.73 | 3.07 |
| PEERS AVERAGE | 32.47 | 5.22 |
Sign in to see all peers for Asensus Surgical Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.